Wyeth discloses new CEO's salary

Wonder what a big cheese in Big Pharma earn these days? Well, Wyeth told the Securities & Exchange Commission that it plans to pay its new chief Bernard Poussot (photo) $1.5 million in base salary, plus 120,000 restricted stock units that start vesting in three years. Meanwhile, its non-employee directors will get $220,000 annually in 2008 and 2009.

Remember, though, that base pay is just that. According to Forbes, Wyeth's current CEO, Robert Essner, raked in $25.66 million in 2006, including base pay, bonuses, stock, and perks.

- read the AP report
- see the figures on Essner in Forbes

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.